Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Amortization of Deferred Charges (2018 - 2025)

Guided Therapeutics' Amortization of Deferred Charges history spans 8 years, with the latest figure at $54000.0 for Q3 2025.

  • For Q3 2025, Amortization of Deferred Charges rose 145.45% year-over-year to $54000.0; the TTM value through Sep 2025 reached $210000.0, up 100.0%, while the annual FY2024 figure was $93000.0, 28.46% down from the prior year.
  • Amortization of Deferred Charges for Q3 2025 was $54000.0 at Guided Therapeutics, down from $68000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $172000.0 in Q2 2021 and bottomed at $14000.0 in Q3 2021.
  • The 5-year median for Amortization of Deferred Charges is $33000.0 (2022), against an average of $46052.6.
  • The largest annual shift saw Amortization of Deferred Charges crashed 86.41% in 2021 before it skyrocketed 277.78% in 2025.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $70000.0 in 2021, then plummeted by 54.29% to $32000.0 in 2022, then grew by 3.12% to $33000.0 in 2023, then tumbled by 36.36% to $21000.0 in 2024, then skyrocketed by 157.14% to $54000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Amortization of Deferred Charges are $54000.0 (Q3 2025), $68000.0 (Q2 2025), and $67000.0 (Q1 2025).